Korean Drug Co., Ltd. (KOSDAQ:014570)
South Korea · Delayed Price · Currency is KRW 3,395.00
-55.00 (-1.59%)
At close: May 29, 2026
Korean Drug Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 6,912 | 6,512 | 2,995 | -4,917 | 11,809 | 9,042 |
Depreciation & Amortization | 1,966 | 1,969 | 2,069 | 1,749 | 1,383 | 1,470 |
Loss (Gain) From Sale of Assets | 4.8 | -0.31 | -3.56 | 3.68 | -2.81 | -1.13 |
Loss (Gain) From Sale of Investments | 33.3 | 180.6 | -72.9 | -132.87 | 383.6 | 359.46 |
Provision & Write-off of Bad Debts | 190.01 | - | - | - | - | - |
Other Operating Activities | 996.84 | 2,616 | -513.96 | 2,118 | -801.33 | 1,384 |
Change in Accounts Receivable | -2,250 | -205.06 | 4,806 | 3,566 | -1,390 | -948.64 |
Change in Inventory | 4,013 | 3,507 | -1,605 | -4,657 | -971.78 | -2,149 |
Change in Accounts Payable | 269.44 | 672.64 | -1,351 | 1,916 | -3,208 | 550.5 |
Change in Other Net Operating Assets | -1,035 | -2,141 | -1,455 | -1,645 | -1,288 | -900.83 |
Operating Cash Flow | 11,100 | 13,110 | 4,869 | -1,999 | 5,913 | 8,806 |
Operating Cash Flow Growth | 0.57% | 169.27% | - | - | -32.86% | -28.58% |
Capital Expenditures | -466.77 | -457 | -1,027 | -120.7 | -6,093 | -1,146 |
Sale of Property, Plant & Equipment | 0.31 | 0.32 | 7.46 | 1.12 | 5.86 | 4.5 |
Sale (Purchase) of Intangibles | -15.09 | -18.04 | -15.71 | -466.7 | -384.22 | 157.73 |
Investment in Securities | -5,206 | -10,182 | -9,830 | 18,159 | 894.66 | -6,980 |
Other Investing Activities | 104.16 | 125 | -23.96 | -5,299 | 175 | -291 |
Investing Cash Flow | -5,583 | -10,532 | -10,889 | 12,274 | -5,401 | -8,254 |
Long-Term Debt Repaid | - | -84.21 | -88.34 | -82.46 | -76.55 | -75.69 |
Total Debt Repaid | -79.08 | -84.21 | -88.34 | -82.46 | -76.55 | -75.69 |
Net Debt Issued (Repaid) | -79.08 | -84.21 | -88.34 | -82.46 | -76.55 | -75.69 |
Issuance of Common Stock | 35.9 | 24.61 | 133.7 | 18.31 | 3.61 | 24.01 |
Repurchase of Common Stock | - | - | - | - | - | -1,103 |
Dividends Paid | -1,948 | -1,730 | -1,618 | -1,941 | -1,833 | -1,634 |
Other Financing Activities | 0 | 0 | - | - | 0 | 0 |
Financing Cash Flow | -1,991 | -1,790 | -1,573 | -2,005 | -1,906 | -2,789 |
Foreign Exchange Rate Adjustments | 24.34 | -5.41 | 6.89 | -7.09 | -20.35 | 10.95 |
Miscellaneous Cash Flow Adjustments | 0 | 0 | 0 | 0 | 0 | - |
Net Cash Flow | 3,550 | 782.47 | -7,586 | 8,263 | -1,415 | -2,227 |
Free Cash Flow | 10,633 | 12,653 | 3,842 | -2,119 | -180.15 | 7,660 |
Free Cash Flow Growth | 4.73% | 229.34% | - | - | - | -33.92% |
Free Cash Flow Margin | 16.94% | 20.24% | 5.26% | -2.60% | -0.22% | 10.29% |
Free Cash Flow Per Share | - | 1169.63 | 356.01 | -196.53 | -16.71 | 701.12 |
Cash Interest Paid | 2.82 | 3.88 | 4.24 | 3.02 | 2.1 | 1.53 |
Cash Income Tax Paid | 1,053 | 812.44 | 3,792 | 12,140 | 3,383 | 2,274 |
Levered Free Cash Flow | 9,405 | 11,770 | 3,630 | 7,388 | -2,709 | 6,243 |
Unlevered Free Cash Flow | 9,408 | 11,772 | 3,632 | 7,390 | -2,707 | 6,244 |
Change in Working Capital | 996.68 | 1,833 | 395.21 | -819.69 | -6,858 | -3,448 |